Hoffman Health Partners

11/21/2025

The office will be Closed on November 27 & 28 for the Thanksgiving Holiday. Be safe & enjoy your families 🦃

11/13/2025

SPOTS ARE STILL AVAIABLE TODAY UNTIL 2PM!

The newest Colon Cancer Screeing is here! We are excited to announce we will be hosting a Shield Drawing Day on November 13th at the office. To be eligible for Shield you must be age 45 - 85 and have Tricare, Medicare, or a Medicare Advantage insurance. Call the office to get place on the list 5702684096.

The term "shield colon cancer test" refers to the Guardant Shield test, a blood-based screening option for colorectal cancer. It is manufactured by Guardant Health and was approved by the FDA in July 2024 for average-risk adults aged 45 and older.
How the Guardant Shield test works
The test is a liquid biopsy that detects cancer-related alterations in cell-free DNA (cfDNA), which are released from tumors into the bloodstream.
A healthcare provider performs a simple blood draw using the Guardant Shield Blood Collection Kit.
The blood sample is sent to a lab for analysis.
The lab analyzes the cfDNA for genomic mutations, methylation, and fragmentation patterns that are associated with colorectal cancer.
The results are reported as either "positive" or "negative".
Test results and their meaning
Positive result: A positive result means a signal associated with colorectal cancer was detected, but it does not confirm a cancer diagnosis. A follow-up colonoscopy is required to investigate the result. The test has a 10% false-positive rate, meaning 1 in 10 average-risk people without advanced neoplasia will incorrectly receive a positive result.
Negative result: A negative result means a signal was not detected, but it does not guarantee the absence of colorectal cancer or advanced precancerous polyps. Ongoing screening is still necessary. The test missed 17% of colorectal cancer cases in clinical trials, particularly early-stage cancers.

11/12/2025

TOMORROW IS THE DAY! Blood draws are being done 10am - 2pm. Please call now to get placed on the list! If you have no interest in a Colonoscopy or as our patients say " p**p in a box" Cologuard this is a great opportunity to still screen for Colorectal Cancer.

The newest Colon Cancer Screeing is here! We are excited to announce we will be hosting a Shield Drawing Day on November 13th at the office. To be eligible for Shield you must be age 45 - 85 and have Tricare, Medicare, or a Medicare Advantage insurance. Call the office to get place on the list 5702684096.

The term "shield colon cancer test" refers to the Guardant Shield test, a blood-based screening option for colorectal cancer. It is manufactured by Guardant Health and was approved by the FDA in July 2024 for average-risk adults aged 45 and older.
How the Guardant Shield test works
The test is a liquid biopsy that detects cancer-related alterations in cell-free DNA (cfDNA), which are released from tumors into the bloodstream.
A healthcare provider performs a simple blood draw using the Guardant Shield Blood Collection Kit.
The blood sample is sent to a lab for analysis.
The lab analyzes the cfDNA for genomic mutations, methylation, and fragmentation patterns that are associated with colorectal cancer.
The results are reported as either "positive" or "negative".
Test results and their meaning
Positive result: A positive result means a signal associated with colorectal cancer was detected, but it does not confirm a cancer diagnosis. A follow-up colonoscopy is required to investigate the result. The test has a 10% false-positive rate, meaning 1 in 10 average-risk people without advanced neoplasia will incorrectly receive a positive result.
Negative result: A negative result means a signal was not detected, but it does not guarantee the absence of colorectal cancer or advanced precancerous polyps. Ongoing screening is still necessary. The test missed 17% of colorectal cancer cases in clinical trials, particularly early-stage cancers.

10/30/2025

The newest Colon Cancer Screeing is here! We are excited to announce we will be hosting a Shield Drawing Day on November 13th at the office. To be eligible for Shield you must be age 45 - 85 and have Tricare, Medicare, or a Medicare Advantage insurance. Call the office to get place on the list 5702684096.

The term "shield colon cancer test" refers to the Guardant Shield test, a blood-based screening option for colorectal cancer. It is manufactured by Guardant Health and was approved by the FDA in July 2024 for average-risk adults aged 45 and older.
How the Guardant Shield test works
The test is a liquid biopsy that detects cancer-related alterations in cell-free DNA (cfDNA), which are released from tumors into the bloodstream.
A healthcare provider performs a simple blood draw using the Guardant Shield Blood Collection Kit.
The blood sample is sent to a lab for analysis.
The lab analyzes the cfDNA for genomic mutations, methylation, and fragmentation patterns that are associated with colorectal cancer.
The results are reported as either "positive" or "negative".
Test results and their meaning
Positive result: A positive result means a signal associated with colorectal cancer was detected, but it does not confirm a cancer diagnosis. A follow-up colonoscopy is required to investigate the result. The test has a 10% false-positive rate, meaning 1 in 10 average-risk people without advanced neoplasia will incorrectly receive a positive result.
Negative result: A negative result means a signal was not detected, but it does not guarantee the absence of colorectal cancer or advanced precancerous polyps. Ongoing screening is still necessary. The test missed 17% of colorectal cancer cases in clinical trials, particularly early-stage cancers.

09/18/2025

These guys from M-R Maintenance Rentals have been busy all day tearing it up! The repaving project is moving along nicely.

To the patients that have been understanding as to why the office is closed we would like to say THANK YOU! We definitely need to spread kidness in this world!

09/18/2025

Reminder the office is closed for in-person visits. We are available by phone only.

09/16/2025

ATTENTION PATIENTS!

09/12/2025

The lab is closed today please go to the hospital for all blood draws

08/20/2025

08/05/2025

Danville, Pa. — Geisinger Behavioral Health Center Danville, at 206 Maria Hall Drive, will open its doors and begin accepting patients on Tuesday, Aug. 5.

07/28/2025

Attention Aetna patients..... we have been made aware that a letter has been sent stating that we are leaving the network. This is not true and the necessary paperwork has been filed with them. You do not need to change providers. Any questions please call the office at 570-268-4096